CA 19.9

Pancreas

Report in 4Hrs

At Home

No Fasting Required

Details

CA 19-9 is a glycoprotein (sugar-coated protein) that is produced in pancreatic and biliary ductal cells and is released into the blood

₹499₹1,210

59% OFF

FREE:

Ai Insights

CA 19.9 Test Information Guide

Why is it done?
- CA 19.9 (Carbohydrate Antigen 19.9) is a tumor marker protein produced by cancer cells and some normal cells. This test measures the level of CA 19.9 in the blood.
- Primary indications include: screening and monitoring pancreatic cancer, monitoring colorectal cancer, detecting gastric (stomach) cancer, assessing bile duct cancer (cholangiocarcinoma), and monitoring ovarian cancer in some cases.
- Typical timing: Ordered when cancer is suspected, at baseline before treatment initiation, periodically during cancer treatment to assess response, and regularly after treatment completion for recurrence detection.
- Most commonly used in pancreatic cancer where it is the primary tumor marker, with sensitivity increasing at advanced disease stages.
Normal Range
- Normal/Reference Range: Less than 37 U/mL (units per milliliter) is generally considered normal.
- Some laboratories may use slightly different cutoff values (ranging from 33-40 U/mL), so interpretation should consider the specific reference range provided by the testing laboratory.
- Unit of Measurement: U/mL (Units per Milliliter). This is a standardized measurement used for tumor markers in blood serum.
- How to Interpret:
- Normal Result (Negative): Less than 37 U/mL suggests absence of elevated tumor marker; however, does not completely rule out cancer, particularly in early stages.
- Elevated Result (Positive): Greater than 37 U/mL may indicate presence of cancer or benign conditions; further investigation is warranted.
- Borderline Values: Results in the range of 37-100 U/mL warrant clinical correlation and may require additional imaging or diagnostic testing.
- What is Important: CA 19.9 is most useful as a monitoring tool rather than a screening or diagnostic test alone, as it can be elevated in both malignant and benign conditions.
Interpretation
- Mildly Elevated (37-200 U/mL): May suggest early stage disease or benign conditions such as pancreatitis, cystic fibrosis, cirrhosis, inflammatory bowel disease, or cholecystitis. Clinical context and imaging are essential.
- Moderately Elevated (200-1000 U/mL): Suggests probable malignancy, particularly pancreatic cancer. Correlation with imaging findings (CT, MRI, ultrasound) is critical for confirmation.
- Markedly Elevated (>1000 U/mL): Strongly suggests advanced malignancy or widespread disease. Indicates need for urgent further investigation and specialist consultation.
- Declining Levels During Treatment: Suggests positive treatment response and indicates therapy is effective.
- Rising Levels After Treatment: May indicate cancer recurrence or progression, requiring urgent physician notification and further evaluation.
- Factors Affecting Readings: Benign pancreatic disease, liver disease, smoking status, inflammatory conditions, Lewis antigen negativity (5-10% of population may not produce CA 19.9), recent surgery or endoscopy, and certain medications can influence results.
- Clinical Significance: Best used for monitoring known cancer patients and assessing treatment response. Cannot be used as sole diagnostic criterion. Serial measurements are more valuable than single isolated values for clinical decision-making.
- Limitations: Sensitivity ranges from 40-90% depending on cancer stage; specificity is limited as elevation can occur with benign disease; not recommended for general population screening due to low positive predictive value.
Associated Organs
- Primary Organ Systems: Pancreas (most commonly affected), colon and rectum, stomach, bile ducts, and liver. CA 19.9 is produced by adenocarcinoma cells in these gastrointestinal organs.
- Malignancies Associated: Pancreatic cancer (highest association), colorectal cancer, gastric cancer, bile duct cancer (cholangiocarcinoma), hepatocellular carcinoma, lung cancer (adenocarcinoma type), breast cancer (in some cases), and ovarian cancer.
- Benign Conditions Associated with Elevation: Chronic pancreatitis, acute pancreatitis, pancreatic cysts, cirrhosis, hepatitis, cystic fibrosis, peptic ulcer disease, gastritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), endometriosis, and benign ovarian cysts.
- Pancreatic Cancer Specifics: CA 19.9 is elevated in approximately 80-85% of advanced pancreatic cancer cases but only 50% of early-stage disease cases. Used for initial staging and recurrence monitoring.
- Colorectal Cancer: CA 19.9 elevation associated with advanced disease and poor prognosis. Higher levels correlate with metastatic disease.
- Bile Duct Cancer: CA 19.9 often significantly elevated (>1000 U/mL), used for diagnosis, prognosis assessment, and treatment monitoring.
- Complications of Abnormal Results: Delayed diagnosis if benign conditions are initially suspected; potential for unnecessary invasive procedures; psychological distress from uncertain results; and need for repeated testing causing anxiety.
Follow-up Tests
- Imaging Studies: Computed Tomography (CT) of abdomen and pelvis, Magnetic Resonance Imaging (MRI) with MRCP for pancreatic or biliary evaluation, Endoscopic Ultrasound (EUS) for tissue confirmation and staging, Positron Emission Tomography (PET-CT) for metastatic disease detection.
- Tissue Confirmation: Endoscopic biopsy, percutaneous needle biopsy, or fine needle aspiration (FNA) under ultrasound or CT guidance may be necessary to confirm malignancy.
- Additional Tumor Markers: CEA (carcinoembryonic antigen) for colorectal cancer, AFP (alpha-fetoprotein) for hepatocellular carcinoma, CA 15.3 or CA 27.29 for breast cancer assessment.
- Liver Function Tests: AST, ALT, ALP, bilirubin to assess hepatic involvement or underlying liver disease contributing to CA 19.9 elevation.
- Pancreatic Enzymes: Amylase and lipase if pancreatitis is suspected as benign cause of CA 19.9 elevation.
- Complete Blood Count: To assess for anemia, thrombocytopenia, or leukopenia suggesting advanced malignancy.
- Monitoring Frequency for Cancer Patients: Every 4-8 weeks during active treatment, every 3 months for 2 years post-treatment, every 6 months for years 2-5 post-treatment, and annually after 5 years if patient remains cancer-free.
- Colonoscopy or Sigmoidoscopy: For colorectal cancer investigation if CA 19.9 is elevated and colorectal malignancy is suspected.
- Upper Endoscopy: For evaluation of gastric or esophageal involvement if indicated by clinical presentation.
Fasting Required?
- Fasting Requirement: No, fasting is NOT required for CA 19.9 testing. This test can be performed on a non-fasting blood sample.
- Sample Collection: Blood sample is collected via venipuncture into a serum separator tube (SST) or standard red-top tube.
- Timing: Test can be performed at any time of day; morning collection is often preferred but not mandatory.
- Medications: No specific medications need to be held or avoided before CA 19.9 testing. Patients should continue their regular medications as prescribed.
- Patient Preparation: Wear loose-fitting clothing with sleeves that can be rolled up easily to facilitate blood draw. Stay well-hydrated, as dehydration can concentrate blood components. Avoid excessive physical exertion immediately before testing.
- Special Considerations: If recent endoscopy or biopsy was performed, results may be temporarily elevated; testing should ideally be delayed 1-2 weeks if possible. Inform healthcare provider of any recent procedures.
- Test Processing: Blood sample is allowed to clot, then centrifuged to separate serum. Serum is then tested using immunoassay methods. Results typically available within 24-48 hours.
- Storage: Serum samples can be refrigerated for several days if testing is delayed, or frozen for longer-term storage without compromising test integrity.

How our test process works!